MetaVia (MTVA) Net Equity Issued and Repurchased (2015 - 2024)
MetaVia's (MTVA) quarterly Net Equity Issued and Repurchased came in at $20.0 million in Q2 2024, up 1233.33% on a QoQ basis from $1.5 million in Q1 2015.
MetaVia (MTVA) Net Equity Issued and Repurchased (2015 - 2024) Analysis & Trends
MetaVia (MTVA) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $20.0 million in Q2 2024.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $20.0 million in Q2 2024, while the trailing twelve-month figure through Mar 2015 was $1.5 million (changed N/A YoY) and the FY2025 annual result came in at $1.2 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased improved to $20.0 million in Q2 2024, from $1.5 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $20.0 million in Q2 2024 to a low of $20.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 20.00 Mn |
| Jun 30, 2024 | 20.00 Mn |
| Mar 31, 2015 | 1.50 Mn |
| Mar 31, 2015 | 1.50 Mn |